Etoricoxib Intermediate Synthesis via Simultaneous Addition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The existing methods for synthesizing 1-(6-methylpyridin-3-yl)-2-[4-(methylsulfonyl)phenyl]ethanone, an intermediate for the pharmaceutical active ingredient Etoricoxib, suffer from low yields and significant impurity formation, particularly the impurity '408', which is difficult to remove without yield loss.
Innovation Solution
A process involving the simultaneous addition of the Grignard reagent and the ester of 6-methylpyridine-3-carboxylic acid to (4-methylsulfonyl)phenyl acetic acid or its alkaline salt in the presence of an organic solvent, such as THF, at controlled temperatures, significantly reduces impurity '408' formation while maintaining high yields.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If 3 equivalents of Grignard reagent are used to increase molar yield, then the reaction goes to completion with similar yields, but the product contains unacceptable amounts of impurity '408' (around 3%)
Solution Approach 1:
The patent applies preliminary action by converting (4-methylsulfonyl)phenyl acetic acid to its dianion form before adding the Grignard reagent and ester. This pre-preparation of the reactive species ensures that the Grignard reagent reacts with the pre-formed dianion rather than generating it in situ, which prevents the formation of impurity '408' while maintaining high yields.
Solution Approach 2:
The patent employs periodic action through the sequential addition of reagents in three portions with intervals between them. The Grignard reagent and ester are added alternately in three separate steps, allowing controlled reaction progression that prevents impurity formation while ensuring complete conversion to the desired product.
2Productivity
If sequential addition of Grignard reagent and ester is performed in three portions, then the reaction progresses, but the product contains 2 to 4 percent of impurity '408'
Solution Approach 1:
The key innovation is performing the preliminary action of converting the acid to its dianion form before adding any Grignard reagent or ester. This pre-formed dianion then reacts with the alternately added Grignard reagent and ester, ensuring controlled reaction progression without impurity formation, unlike the conventional sequential addition method.
3Ease of manufacture
If oxidation with hydrogen peroxide catalysed by sodium tungstate is used as the last step, then the synthesis follows the known method, but the process involves hazardous oxidants and tungsten-based catalysts
Solution Approach 1:
The patent applies the taking out principle by completely removing the oxidation step involving hydrogen peroxide and sodium tungstate from the synthesis pathway. The desired product is obtained directly through the Grignard reaction followed by hydrolysis, eliminating the need for hazardous oxidants and tungsten-based catalysts while maintaining synthetic feasibility.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This process achieves yields of 78%-88% with impurity '408' levels below 0.6%, avoiding the use of hazardous oxidants and tungsten-based catalysts, and allows for easier purification and industrial applicability by simplifying the synthetic steps.
Implementation Method 1
the addition of the two reagents such as the ester of the 6-methylpyridine-3-carboxylic acid of formula (III) and the Grignard reagent to the (4-methylsulfonyl)phenyl acetic acid of formula (IV) or to the alkaline salt of the (4-methylsulfonyl) phenyl acetic acid of formula (II)
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention refers to a novel process for the preparation of 1-(6-methylpyridin-3-yl)-2-[4-(methylsulfonyl)phenyl]ethanone, an intermediate of the synthesis of Etoricoxib, an active ingredient on which the Arcoxia drug is based.